Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking through the pain: could uncovering hidden emotions relieve chronic symptoms?

NCT ID NCT06682104

Symptom relief Sponsor: Daniel Maroti Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether a short-term, intensive talk therapy called ISTDP can help people whose physical symptoms—like chronic pain, fatigue, or stomach issues—have not improved with other treatments. The therapy focuses on uncovering and processing unconscious emotions that may be fueling the symptoms. Twenty-five adults who have already had a medical evaluation and still experience significant distress will participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intensive short-term psychodynamic psychotherapy (ISTDP)
What this could lead to
If it works, this could offer a new option for people with chronic physical symptoms that have not responded to standard medical or psychological care.
What could go wrong
This is a very small early trial with only 25 participants, so results may not apply widely. The therapy is intensive and may not be suitable for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

25 people

The number who actually took part.

Started

Feb 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The participant certifies that they have undergone a medical evaluation for their physical symptoms. * The participant rates either moderate distress from physical symptoms on the PHQ-15 form (over 10 points) or significant distress from a single physical symptom (at least 2 points for that symptom). * The participant expresses interest in exploring whether emotional factors, such as stress, may contribute to their symptom profile. * Any prescribed medications must have been stable for at least 1 month. * Participants must meet the criteria for non-response/treatment resistance, i.e., no reliable change in PHQ-15. Exclusion Criteria: * Participants suffer from ongoing substance abuse (alcohol or drugs) or are assessed to have severe mental health issues (psychotic disorders, moderate to high suicide risk, antisocial personality disorder, etc.). * Participants are currently prescribed medications that are clearly addictive and sedative in nature (e.g., benzodiazepines). * Participants are involved in other psychological treatments focused on physical symptoms. However, other psychological treatments are allowed as long as the supportive therapy does not occur more than once a month. * Participants do not have sufficient proficiency in the Swedish language. * Somatic symptoms is judged to be need further medically evaluation or treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Functional somatic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Medically Unexplained Symptoms somatization disorder somatoform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Functional somatic disorder Functional somatic syndrome Medically unexplained symptoms Persistent physical symptoms Somatic symptom disorder

Contacts and locations

Locations

  • Stockholm University

    Stockholm, 10691, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.